Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway

Nouf Mohamed Al-Rasheed, Nawal Mohamed Al-Rasheed, Maha Abdelrahman Al-Amin, Iman Huesein Hasan, Hanaa Najeeb Al-Ajmi, Raeesa Ahmed Mohammad, Hala Aboulfotooh Attia

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Context: Fibrates, the ligands of peroxisome profileferator-activated receptor-α have been shown to have a renal protective action in diabetic nephropathy (DN). Objective: This study aimed to elucidate the effect of fenofibrate on renal transforming growth factor-β1 (TGF-β1) and Smad3 in Streptozotocin (STZ)-induced DN. Methods: Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin (55 mg/kg). Diabetic rats were given fenofibrate (100 mg/kg, p.o.). After 12 weeks, diabetic nephropathy biomarkers were assessed. The mRNA expression of collage I and III, TGF-β1 and Smad3 and were detected by RT–PCR. Results: Fenofibrate reduced significantly serum creatinine, kidney/body weight ratio, serum albumin excretion Collage I & III, TGF-β1 and Smad3 mRNA expression. Conclusions: Our results give further insights into the mechanisms underlying the protective role of fenofibrate in DN, suggesting that interference with TGF-β1/Smad3 signaling pathway may be a useful therapeutic approach to prevent DN.

Original languageEnglish
Pages (from-to)186-194
Number of pages9
JournalArchives of Physiology and Biochemistry
Volume122
Issue number4
DOIs
Publication statusPublished - 7 Aug 2016

Fingerprint

Fenofibrate
Diabetic Nephropathies
Transforming Growth Factors
Streptozocin
Kidney
Fibric Acids
Messenger RNA
Peroxisomes
Intraperitoneal Injections
Serum Albumin
Creatinine
Biomarkers
Body Weight
Ligands
Serum

Keywords

  • Animals
  • antibody
  • diabetic nephropathy
  • drugs
  • fenofibrate
  • Smad3
  • TGF-β1

Cite this

Al-Rasheed, Nouf Mohamed ; Al-Rasheed, Nawal Mohamed ; Al-Amin, Maha Abdelrahman ; Hasan, Iman Huesein ; Al-Ajmi, Hanaa Najeeb ; Mohammad, Raeesa Ahmed ; Attia, Hala Aboulfotooh. / Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway. In: Archives of Physiology and Biochemistry. 2016 ; Vol. 122, No. 4. pp. 186-194.
@article{ec9c14b696304d19ab22a533f35052e1,
title = "Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway",
abstract = "Context: Fibrates, the ligands of peroxisome profileferator-activated receptor-α have been shown to have a renal protective action in diabetic nephropathy (DN). Objective: This study aimed to elucidate the effect of fenofibrate on renal transforming growth factor-β1 (TGF-β1) and Smad3 in Streptozotocin (STZ)-induced DN. Methods: Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin (55 mg/kg). Diabetic rats were given fenofibrate (100 mg/kg, p.o.). After 12 weeks, diabetic nephropathy biomarkers were assessed. The mRNA expression of collage I and III, TGF-β1 and Smad3 and were detected by RT–PCR. Results: Fenofibrate reduced significantly serum creatinine, kidney/body weight ratio, serum albumin excretion Collage I & III, TGF-β1 and Smad3 mRNA expression. Conclusions: Our results give further insights into the mechanisms underlying the protective role of fenofibrate in DN, suggesting that interference with TGF-β1/Smad3 signaling pathway may be a useful therapeutic approach to prevent DN.",
keywords = "Animals, antibody, diabetic nephropathy, drugs, fenofibrate, Smad3, TGF-β1",
author = "Al-Rasheed, {Nouf Mohamed} and Al-Rasheed, {Nawal Mohamed} and Al-Amin, {Maha Abdelrahman} and Hasan, {Iman Huesein} and Al-Ajmi, {Hanaa Najeeb} and Mohammad, {Raeesa Ahmed} and Attia, {Hala Aboulfotooh}",
year = "2016",
month = "8",
day = "7",
doi = "10.3109/13813455.2016.1164186",
language = "English",
volume = "122",
pages = "186--194",
journal = "Archives of Physiology and Biochemistry",
issn = "1381-3455",
publisher = "Informa Healthcare",
number = "4",

}

Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway. / Al-Rasheed, Nouf Mohamed; Al-Rasheed, Nawal Mohamed; Al-Amin, Maha Abdelrahman; Hasan, Iman Huesein; Al-Ajmi, Hanaa Najeeb; Mohammad, Raeesa Ahmed; Attia, Hala Aboulfotooh.

In: Archives of Physiology and Biochemistry, Vol. 122, No. 4, 07.08.2016, p. 186-194.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway

AU - Al-Rasheed, Nouf Mohamed

AU - Al-Rasheed, Nawal Mohamed

AU - Al-Amin, Maha Abdelrahman

AU - Hasan, Iman Huesein

AU - Al-Ajmi, Hanaa Najeeb

AU - Mohammad, Raeesa Ahmed

AU - Attia, Hala Aboulfotooh

PY - 2016/8/7

Y1 - 2016/8/7

N2 - Context: Fibrates, the ligands of peroxisome profileferator-activated receptor-α have been shown to have a renal protective action in diabetic nephropathy (DN). Objective: This study aimed to elucidate the effect of fenofibrate on renal transforming growth factor-β1 (TGF-β1) and Smad3 in Streptozotocin (STZ)-induced DN. Methods: Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin (55 mg/kg). Diabetic rats were given fenofibrate (100 mg/kg, p.o.). After 12 weeks, diabetic nephropathy biomarkers were assessed. The mRNA expression of collage I and III, TGF-β1 and Smad3 and were detected by RT–PCR. Results: Fenofibrate reduced significantly serum creatinine, kidney/body weight ratio, serum albumin excretion Collage I & III, TGF-β1 and Smad3 mRNA expression. Conclusions: Our results give further insights into the mechanisms underlying the protective role of fenofibrate in DN, suggesting that interference with TGF-β1/Smad3 signaling pathway may be a useful therapeutic approach to prevent DN.

AB - Context: Fibrates, the ligands of peroxisome profileferator-activated receptor-α have been shown to have a renal protective action in diabetic nephropathy (DN). Objective: This study aimed to elucidate the effect of fenofibrate on renal transforming growth factor-β1 (TGF-β1) and Smad3 in Streptozotocin (STZ)-induced DN. Methods: Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin (55 mg/kg). Diabetic rats were given fenofibrate (100 mg/kg, p.o.). After 12 weeks, diabetic nephropathy biomarkers were assessed. The mRNA expression of collage I and III, TGF-β1 and Smad3 and were detected by RT–PCR. Results: Fenofibrate reduced significantly serum creatinine, kidney/body weight ratio, serum albumin excretion Collage I & III, TGF-β1 and Smad3 mRNA expression. Conclusions: Our results give further insights into the mechanisms underlying the protective role of fenofibrate in DN, suggesting that interference with TGF-β1/Smad3 signaling pathway may be a useful therapeutic approach to prevent DN.

KW - Animals

KW - antibody

KW - diabetic nephropathy

KW - drugs

KW - fenofibrate

KW - Smad3

KW - TGF-β1

UR - http://www.scopus.com/inward/record.url?scp=84962439016&partnerID=8YFLogxK

U2 - 10.3109/13813455.2016.1164186

DO - 10.3109/13813455.2016.1164186

M3 - Article

VL - 122

SP - 186

EP - 194

JO - Archives of Physiology and Biochemistry

JF - Archives of Physiology and Biochemistry

SN - 1381-3455

IS - 4

ER -